Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Global gene expression profiles of mouse ESCs, disease-specific iPSCs, and gene-corrected iPSCs


ABSTRACT: The use of patient-derived induced pluripotent stem (iPS) cells as treatment for genetic diseases entails genetic repair or transfer of genetic information as a prerequisite. We have chosen the murine model of tyrosinemia type 1 (fumarylacetoacetate hydrolase deficiency; FAH(-/-) mice) as a paradigm for hereditary metabolic liver disorders and evaluated fibroblast-derived FAH(-/-)-iPS cell lines as targets for gene correction. By aggregating FAH(-/-)-iPS cells with tetraploid embryos, we obtained FAH-/--iPS cell–derived mice, which exhibited the phenotype of the founding FAH(-/-)-mice. We then rescued the diseased phenotype by lentiviral transduction of FAH-cDNA and performed embryo aggregation with these gene-corrected FAHgc-iPS cells to obtain viable healthy mice. Our results demonstrate that iPS cell technology is a valid approach to establish mouse disease models directly from somatic cells bearing genetic defects. Furthermore, established iPS cell lines can be genetically manipulated without loss of pluripotency for treatment of genetic diseases. 6 samples: 1 MEF, 1ESC, 4 iPSCs

ORGANISM(S): Mus musculus

SUBMITTER: Boris Greber 

PROVIDER: E-GEOD-21343 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

Similar Datasets

2010-04-16 | GSE21343 | GEO
2022-02-28 | GSE188987 | GEO
2012-07-16 | E-GEOD-38963 | biostudies-arrayexpress
2014-03-28 | E-GEOD-53485 | biostudies-arrayexpress
2014-11-12 | GSE61287 | GEO
2008-06-11 | E-GEOD-11098 | biostudies-arrayexpress
2020-01-17 | GSE93713 | GEO
2016-09-14 | GSE77995 | GEO
2022-12-28 | GSE218101 | GEO
| S-EPMC4545662 | biostudies-literature